Verve Therapeutics Inc (VERV)
6.55
-0.11
(-1.65%)
USD |
NASDAQ |
Apr 19, 12:21
Verve Therapeutics Cash and Short Term Investments (Quarterly): 623.95M for Dec. 31, 2023
Cash and Short Term Investments (Quarterly) Chart
Historical Cash and Short Term Investments (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 623.95M |
| September 30, 2023 | 485.23M |
| June 30, 2023 | 462.48M |
| March 31, 2023 | 508.69M |
| December 31, 2022 | 554.81M |
| September 30, 2022 | 550.71M |
| June 30, 2022 | 293.56M |
| Date | Value |
|---|---|
| March 31, 2022 | 323.30M |
| December 31, 2021 | 360.44M |
| September 30, 2021 | 389.21M |
| June 30, 2021 | 417.62M |
| March 31, 2021 | 149.52M |
| December 31, 2020 | 72.11M |
Cash and Short Term Investments Definition
Cash and Short Term investments is the sum of two balance sheet line items: cash and equivalents and short term investments in marketable securities.
Cash and Short Term Investments (Quarterly) Range, Past 5 Years
72.11M
Minimum
Dec 2020
623.95M
Maximum
Dec 2023
399.36M
Average
417.62M
Median
Jun 2021
Cash and Short Term Investments (Quarterly) Benchmarks
| Acorda Therapeutics Inc | 29.98M |
| Eli Lilly and Co | 2.928B |
| Intellia Therapeutics Inc | 912.22M |
| Beam Therapeutics Inc | 1.190B |
| Editas Medicine Inc | 323.11M |